Scleroderma epidemiology

Rheumatic Disease Clinics of North America

Volumn 29, Issue 2, 2003, Pages 239-254

  Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AUSTRALIA; CAUSE OF DEATH; CLUSTER ANALYSIS; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ETHNOLOGY; GEOGRAPHIC DISTRIBUTION; HEART DISEASE; HEREDITY; HUMAN; INCIDENCE; MORTALITY; NEGRO; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; SCLERODERMA; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; UNITED STATES;

EID: 0038799783     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00022-X     Document Type: Review

References (94)

1. Giordano M. Classification of progressive systemic sclerosis (scleroderma). In: Black CM, Myers AR, editors. Systemic sclerosis (scleroderma). New York: Gower; 1985. p. 21-3.
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
3. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23(3):581-6.
4. Altman RD, Medsger Jr TA, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34(3):403-13.
5. Medsger Jr TA, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971;74(5):714-21.
6. Medsger Jr TA, Masi AT, Rodnan GP, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75(3):369-76.
7. Michet Jr CJ, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue disease in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60(2):105-13.
8. Medsger Jr TA. Comment on scleroderma criteria cooperative study. In: Black CM, Myers AR, editors. Systemic sclerosis (scleroderma). New York: Gower; 1985. p. 16-7.
9. Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997;40(3):441-5.
10. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989;32(8):998-1006.
11. Mayes M, Laing T, Gillespie B, et al. Prevalence, incidence and survival rates of systemic sclerosis in the Detroit Metropolitan Area. Arthritis Rheum 1996;39(supp):S150.
12. D'Angelo WA. Long-term survival of scleroderma renal crisis and malignant hypertension with captopril. In: Black CM, Myers AR, editors. Systemic sclerosis (scleroderma). New York: Gower; 1985. p. 437-45.
13. Hochberg MC, Spector TD. Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 1990;12(1):247-52.
14. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46(3):625-31.
15. Dugowson CE, Koepsell TD, Voigt LF, et al. Rheumatoid arthritis in women: incidence rates in Group Health Cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum 1991;34(12):1502-7.
16. Linos A, Worthington JW, O'Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of its incidence, prevalence, and mortality. Am J Epidemiol 1980;111(1):87-98.
17. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41(7):793-800.
18. Kaipiainen-Seppanen O, Aho K, Isomaki H, et al. Incidence of rheumatoid arthritis in Finland during 1980-1990. Ann Rheum Dis 1996;55(9):608-11.
19. Uramoto KM, Michet Jr CJ, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42(1):46-50.
20. Silman A, Jannini S, Symmons D, et al. An epidemiologic study of scleroderma in the West Midlands. Br J Rheumatol 1988;27(4):286-90.
21. Tamaki T, Mori S, Takehara K. Epidemiologic study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283(6):366-71.
22. Geirsson AJ, Steinsson K, Guthmundsson S, et al. Systemic sclerosis in Iceland. A nationwide epidemiologic study. Ann Rheum Dis 1994;53(8):502-5.
23. Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Int Med J 2001;31(4):220-9.
24. Englert H, Small-McMahon J, Davis K, et al. Systemic sclerosis prevalence and mortality in Sydney 1974-1988. Aust N Z J Med 1999;29(1):42-50.
25. Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 1978;21(4):480-4.
26. Beebe JL, Lacey Jr JV, Mayes MD, et al. Reproductive history, oral contraceptive use, estrogen replacement therapy and the risk of developing scleroderma. Arthritis Rheum 1997;40(Suppl):S100.
27. Pisa FE, Bovenzi M, Romeo L, et al. Reproductive factors and the risk of scleroderma: an Italian case-control study. Arthritis Rheum 2002;46(2):451 -6.
28. Artlett CM, Rasheed M, Russo-Stieglitz KE, et al. Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. Ann Rheum Dis 2002;61(4):346-50.
29. Launay D, Hebbar M, Hatron PY, et al. Relationship between parity and clinical and biological features in patients with systemic sclerosis. J Rheumatol 2001;28(3):509-13.
30. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40(4):734-42.
31. Arnett FC, Bias WB, McLean RH, et al. Connective tissue disease in southeast Georgia. A community-based study of immunogenetic markers and autoantibodies. J Rheumatol 1990;17(8):1029-35.
32. Arnett FC, Reveille JD. Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 1992;18(4):865-92.
33. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995;12(2-4):107-28.
34. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989;32(1):54-60.
35. Reveille JD, Durban E, Goldstein R, et al. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35(2):216-8.
36. Reveille JD, Fischback M, McNearney T, et al, GENISOS Study Group. Systemic sclerosis in three US ethnic groups: a comparison of clinical sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30(5):332-46.
37. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996;39(8):1362-70.
38. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13(5):911-6.
39. Bunker CB, Atherton D, Gray OP, et al. Familial Raynaud's phenomenon and localized scleroderma associated with essential telangiectasia and cytogenetic abnormalities. J R Soc Med 1990;83(8):531-2.
40. Burge KM, Perro HO, Stickler GB. Familial" scleroderma. Arch Dermatol 1969;99(6):681-7.
41. Calvani N, Silvestris F, Dammacco F. Familial systemic sclerosis following exposure to organic solvents and the possible implication of genetic factors. Ann Ital Med Int 2001;16(3):175-8.
42. Camus JP, Eretit I, Reinert P, et al. Familial scleroderma with Sjogren's syndrome and lymphocyte and chromosome abnormalities. Ann Med Interne (Paris) 1970;121(2):149-61.
43. Cook NJ, Silman AJ, Propert J, et al. Features of systemic sclerosis (scleroderma) in an identical twin pair. Br J Rheumatol 1993;32(10):926-8.
44. de Juan MD, Belzunegui J, Belmonte I, et al. An immunogenetic study of familial scleroderma. Ann Rheum Dis 1994;53(9):614-7.
45. De Keyser F, Peene I, Joos R, et al. Occurrence of scleroderma in monozygotic twins. J Rheumatol 2000;27(9):2267-9.
46. Del Rosso A, Pignone A, Giacomelli R, et al. Familial scleroderma: do environmental factors, genes and microchimerism share the same relevance? J Eur Acad Dermatol Venereol 2001;15(1):11-44.
47. Dobzhanskii SI. Familial cases of scleroderma. Vestn Dermatol Venerol 1979;(5):40-2.
48. Fitzgerald EA, Connelly CS, Purcell SM, et al. Familial lichen sclerosus et atrophicus in association with CREST syndrome: a case report. Br J Dermatol 1996;134(6):1144-6.
49. Flores RH, Stevens MB, Arnett FC. Familial occurrence of progressive systemic sclerosis and systemic lupus erythematosus. J Rheumatol 1984;11(3):321-3.
50. Frayha RA, Tabbara KF, Geha RS. Familial CRST syndrome with sicca complex. J Rheumatol 1977;4(1):53-8.
51. Gray RG, Altman RD. Progressive systemic sclerosis in a family: case report of a mother and son and review of the literature. Arthritis Rheum 1977;20(1):35-41.
52. Greger RE, Greger RE. Familial progressive systemic scleroderma. Arch Dermatol 1975;111(1):81-5.
53. Guseva NG, Folomeeva OM, Oskilko TG. Familial systemic scleroderma: a follow-up study of concordant monozygotic twins. Ter Arkh 1981;53(7):43-7.
54. Hietarinta M, Koskimies S, Lassila O, et al. Familial scleroderma: HLA antigens and autoantibodies. Br J Rheumatol 1993;32(4):336-8.
55. Holzmann H, Schlieter A, Altmeyer P, et al. Immunogenetic studies of familial occurrence of progressive systemic scleroderma and circumscribed scleroderma. Hautarzt 1992;43(9):548-53.
56. Lewkonia RM, Bowen TJ. Familial concurrence of pauciarticular syndrome and systemic sclerosis. Clin Rheumatol 1986;5(2):252-5.
57. Maddison PJ, Stephens C, Briggs D, et al. Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group. Medicine (Baltimore) 1993;72(2):103-12.
58. Manolios N, Dunckley H, Chivers T, et al. Immunogenetic analysis of five families with multicase occurrence of scleroderma and/or related variants. J Rheumatol 1995;22(1):85-92.
59. McAndrew GM, Barnes EG. Familial scleroderma. Ann Phys Med 1965;8(4):128-31.
60. McGregor AR, Watson A, Yunis E, et al. Familial clustering of scleroderma spectrum disease. Am J Med 1988;84(6):1023-32.
61. Molta CT, Khan MA, Aponte CJ, et al. Familial occurrence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: report of two kindreds with study of HLA antigens and review of the literature. Clin Exp Rheumatol 1989;7(3):229-36.
62. Muralindar K, Siddaraj KS, Sankaran K, et al. Familial scleroderma. (Case report). J Assoc Physicians India 1978;26(4):307-9.
63. Pereira S, Black C, Welsh K, et al. Autoantibodies and immunogenetics in 30 patients with systemic sclerosis and their families. J Rheumatol 1987;14(4):760-5.
64. Rendall JR, McKenzie AW. Familial scleroderma. Br J Dermatol 1974;91(5):517-22.
65. Rose T, Nothjunge J, Schlote W. Familial occurrence of dermatomyositis and progressive scleroderma after injection of a local anaesthetic for dental treatment. Eur J Pediatr 1985;143(3):225-8.
66. Ruffatti A, Artifoni L, Glorioso S, et al. Prevalence of anticentromere antibody in blood relatives of anticentromere positive patients. J Rheumatol 1985;12(5):940-3.
67. Sasaki T, Denpo K, Ono H, et al. HLA in systemic scleroderma (PSS) and familial scleroderma. J Dermatol 1991;18(1):18-24.
68. Shelkovitz-Shiloh I, Ehrenfeld M, Schewach-Millet M, et al. Coexistence of familial systemic lupus erythematosus and localized scleroderma. Int J Dermatol 1992;31(11):819-20.
69. Soppi E, Lehtonen A, Toivanen A. Familial progressive systemic sclerosis (scleroderma): immunologic analysis of two patients and six siblings from a single kindred. Clin Exp Immunol 1982;50(2):275-82.
70. Stephens CO, Briggs DC, Whyte J, et al. Familial scleroderma-evidence for environmental versus genetic trigger. Br J Rheumatol 1994;33(12):1131-5.
71. Stockman G, Franke M, Kasulke D. Rheumatoid arthritis, progressive systemic sclerosis without skin involvement and mixed collagen disease in a family. Clinical description of a mother and her 3 adult children-studies of HLA antigens and review of the literature. Z Rheumatol 1986;45(1):16-25.
72. Szczepanski A, Jakubowicz K. Familial occurrence of scleroderma. Przegl Dermatol 1972;59(3):361-4.
73. Tajima S, Yamada H. Altered collagen and glycosaminoglycan syntheses in familial scleroderma skin fibroblasts. Dermatology 1995;191(2):115-8.
74. Valenta LJ, Elias AN. Familial scleroderma in a kindred with high incidence of autoimmune disease: correlation with HLA-A1/B8 haplotype. Arch Dermatol 1987;123(11):1438-40.
75. Wanchu A, Misra R. Familial systemic sclerosis-a report of two cases in the same kindred. J Assoc Physicians India 1995;43(9):633-4.
76. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002;4(2):99-107.
77. Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44(6):1359-62.
78. Englert H, Small-McMahon J, Chambers P, et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999;29(1):36-41.
79. Freedman RR, Mayes MD. Familial aggregation of idiopathic Raynaud's disease. Arthritis Rheum 1996;39(7):1189-91.
80. Feghali CA, Wright TM. Epidemiologic and clinical study of twins with scleroderma [abstract]. Arthritis Rheum 1995;38(Suppl):S308.
81. McHugh NJ, Whyte J, Artlett C, et al. Anticentromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serologic and HLA study. Clin Exp Immunol 1994;96(2):267-74.
82. Christy WC, Rodnan GP. Conjugal progressive systemic sclerosis (scleroderma): report of the disease in husband and wife. Arthritis Rheum 1984;27(10):1180-2.
83. Bond C, Pile KD, McNeil JD, et al. South Australian scleroderma register: analysis of deceased patients. Pathology 1998;30(4):386-90.
84. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118(8):602-9.
85. Ferri C, Valentini G, Cozzi F, et al, Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81(6):139-53.
86. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001;60(12):1117-22.
87. Jacobsen SJ, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28(11):2454-9.
88. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81(2):154-67.
89. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988;15(2):276-83.
90. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82(298):139-48.
91. Kaburaki J, Lee CC, Kuwana M, et al. Initial predictors of survival in patients with systemic sclerosis (scleroderma). Keio J Med 1992;41(3):141-5.
92. Knox EG. Detection of clusters. In: Elliot P, editor. Methodology of enquiries into disease clustering. London: Small Areas Health Statistics Unit; 1989. p. 238-42.
93. Silman AJ, Howard Y, Hicklin AJ, et al. Geographic clustering of scleroderma in south and west London. Br J Rheumatol 1990;29(2):93-6.
94. Valesini G, Litta A, Bonavita MS, et al. Geographic clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 1993;11(1):41-7.